Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790751 · ClinicalTrials.gov registry record · Phase 3
Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED
A Phase 3 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 3
- Development phase
- 646
- Enrollment target
NCT00790751 is a Phase 3 study that has completed, run by VIVUS. The registered enrollment target is 646 participants.
The verdict
NCT00790751, a Phase 3 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 646 participants
- Enrollment target
Study Summary
This study is being conducted to compare the safety and efficacy of 3 doses of avanafil to placebo in men with mild to severe erectile dysfunction.
Interventions
- DRUG placebo
- DRUG avanafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790751
The ClinicalTrials.gov registry entry for NCT00790751 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 646 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00790751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790751 about?
NCT00790751 is a clinical study titled "Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED". This study is being conducted to compare the safety and efficacy of 3 doses of avanafil to placebo in men with mild to severe erectile dysfunction.
What is the current status of trial NCT00790751?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 646 participants. The study started on 2008-11. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00790751?
The interventions under investigation include: placebo (DRUG), avanafil (DRUG).
Who is sponsoring clinical trial NCT00790751?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.